Abstract 399P
Background
Currently in Indonesia, colorectal cancer (CRC) is the third most commonly occurring cancer in men and the fourth in women. CRC is mostly diagnosed in the advanced stage, it’s probably caused by the difficulties in detecting colorectal cancer. Identifying risk factors of CRC is very crucial to prevent CRC. CRC risk is expected to rise continually due to dietary patterns, smoking, lack of physical activities, and other practices. This study describes the prevalence of risk factors for CRC in healthy residents of Suluhan village, Bangli District, Bali Province.
Methods
A pre-experimental cross-sectional study-based community was conduct on 18th – 19th May 2019 in Suluhan village to collect data from 77 healthy residents using validated questionnaire. We measured sociodemographic characteristics, physical activity, dietary habits, and lifestyle as risk factors of CRC. Analysis of data using chi-square with p-value ≤0.05 is categorized as significant.
Results
77 respondents were involved in this study with a mean age of 41.94 ± 9.448 years. The majority of participants were female (61 %). Mostly the residents didn’t know CRC (80.6%). The commonest risk factors for CRC among the participants were overconsumption of red meat (2 times/week and >3 times/week) (67.6 %), overweight and obesity (62.4 %), limited consumption of vegetables (62.3 %), low of physical activities (44.1%), smoking (28.6%), and limited consumption of diet fiber (10.4%). Lack of physical activity was found significantly higher in females (p = 0,000), otherwise smoking (p = 0,000) is higher in males.
Conclusions
We conclude that the highest risk factor of CRC in Suluhan village is the overconsumption of red meat, followed by overweight and obesity, limited consumption of vegetables, low physical activities, smoking, and limited consumption of diet fiber sequentially. Dietary and lifestyle risk factors for CRC are prevalent in Suluhan village and likely to increase CRC incidence if educational interventions are not implemented. Greater attention in improving residents’ knowledge of CRC risk is needed to prevent CRC in Suluhan village.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract